Sunitinib

Sunitinib
Clinical data
Trade names	Sutent, others
Other names	SU11248
AHFS/Drugs.com	Monograph
MedlinePlus	a607052
License data	US DailyMed: Sunitinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01EX01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	Unaffected by food
Protein binding	95%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	40 to 60 hours (sunitinib); 80 to 110 hours (metabolite)
Excretion	Fecal (61%) and kidney (16%)
Identifiers
	IUPAC name N-(2-Diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;
CAS Number	557795-19-4 ; as salt: 341031-54-7 ;
PubChem CID	5329102; as salt: 6456015;
IUPHAR/BPS	5713;
DrugBank	DB01268 ; as salt: DBSALT000166;
ChemSpider	4486264 ; as salt: 4958254;
UNII	V99T50803M; as salt: LVX8N1UT73 ;
KEGG	D08552 ; as salt: D06402;
ChEBI	CHEBI:38940 ;
ChEMBL	ChEMBL535 ; as salt: ChEMBL1567;
CompTox Dashboard (EPA)	DTXSID1041134 ;
Chemical and physical data
Formula	C22H27FN4O2
Molar mass	398.482 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C;
	InChI InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12- ; Key:WINHZLLDWRZWRT-ATVHPVEESA-N ; ; as salt: InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1; Key:LBWFXVZLPYTWQI-IPOVEDGCSA-N;
	(what is this?) (verify)

Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

As of August 2021, sunitinib is available as a generic medicine in the US.